625 related articles for article (PubMed ID: 10573115)
1. Cisplatin-epirubicin-paclitaxel weekly administration in advanced breast cancer: a phase I study of the Southern Italy Cooperative Oncology Group.
Frasci G; D'Aiuto G; Comella P; Apicella A; Thomas R; Capasso I; Di Bonito M; Cartenì G; Biglietto M; De Lucia L; Maiorino L; Piccolo S; Bianchi U; D'Aniello R; Lapenta L; Comella G
Breast Cancer Res Treat; 1999 Aug; 56(3):239-52. PubMed ID: 10573115
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin-epirubicin-paclitaxel weekly administration with G-CSF support in advanced breast cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase II study.
Frasci G; D'Aiuto G; Comella P; Thomas R; Capasso I; Di Bonito M; Rivellini F; Carteni G; De Lucia L; Maiorino L; D'Aniello R; Frezza P; Lapenta L; Comella G
Breast Cancer Res Treat; 2000 Jul; 62(2):87-97. PubMed ID: 11016746
[TBL] [Abstract][Full Text] [Related]
3. Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study.
Frasci G; Comella P; D'Aiuto G; Budillon A; Barbarulo D; Thomas R; Capasso I; Casaretti R; Daponte A; Caponigro F; Gravina A; Maiorino L; Caratení G; Gentile A; Comella G
Breast Cancer Res Treat; 1998 May; 49(1):13-26. PubMed ID: 9694607
[TBL] [Abstract][Full Text] [Related]
4. Weekly dose-dense cisplatin-epirubicin-paclitaxel administration with granulocyte colony-stimulating factor support does not substantially improve prognosis in extensive disease small-cell lung cancer. A SICOG phase II study.
Frasci G; Comella P; Carreca I; DeCataldis G; Muci D; Brunetti C; Russo A; Palmeri S; D'Aniello R; Giordano R; D'Aiuto M; Comella G;
Oncology; 2005; 68(2-3):223-9. PubMed ID: 16015038
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin-paclitaxel weekly schedule in advanced solid tumors: a phase I study.
Frasci G; Comella P; Parziale A; Casaretti R; Daponte A; Gravina A; De Rosa L; Gallipoli A; Comella G
Ann Oncol; 1997 Mar; 8(3):291-3. PubMed ID: 9137800
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin-topotecan-paclitaxel weekly administration with G-CSF support for ovarian and small-cell lung cancer patients: a dose-finding study.
Frasci G; Panza N; Comella P; Cartení G; Guida T; Nicolella GP; Natale M; Lombardi R; Apicella A; Pacilio C; Gravina A; Lapenta L; Comella G
Ann Oncol; 1999 Mar; 10(3):355-8. PubMed ID: 10355583
[TBL] [Abstract][Full Text] [Related]
7. A 2-month cisplatin-epirubicin-paclitaxel (PET) weekly combination as primary systemic therapy for large operable breast cancer: a phase II study.
Frasci G; D'Aiuto G; Comella P; Thomas R; Botti G; Di Bonito M; D'Aiuto M; Romano G; Rubulotta MR; Comella G
Ann Oncol; 2005 Aug; 16(8):1268-75. PubMed ID: 15937055
[TBL] [Abstract][Full Text] [Related]
8. Escalating doses of paclitaxel and epirubicin in combination with cisplatin in advanced ovarian epithelial carcinoma: a phase I-II study.
Gebbia V; Di Marco P; Borsellino N; Gebbia N; Valerio MR; Fallica G; Tirrito ML; Valenza R; Citarrella P; Benedetti Panici P
Anticancer Drugs; 2003 Jun; 14(5):359-64. PubMed ID: 12782942
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of a dose-density regimen with fluorouracil, epirubicin, and cyclophosphamide on days 1 and 4 every 14 days with filgrastim support followed by weekly paclitaxel in women with primary breast cancer.
Pietri E; Andreis D; Fabbri F; Menna C; Schirone A; Kopf B; Rocca A; Amadori D; De Giorgi U
Oncologist; 2015 Mar; 20(3):239-40. PubMed ID: 25637379
[TBL] [Abstract][Full Text] [Related]
10. Weekly paclitaxel and cisplatin with concurrent radiotherapy in locally advanced non-small-cell lung cancer: a phase I study.
Frasci G; Comella P; Scoppa G; Guida C; Gravina A; Fiore F; Casaretti R; Daponte A; Parziale A; Comella G
J Clin Oncol; 1997 Apr; 15(4):1409-17. PubMed ID: 9193333
[TBL] [Abstract][Full Text] [Related]
11. Phase I dose escalation study of gemcitabine and paclitaxel plus colony-stimulating factors in previously treated patients with advanced breast and ovarian cancer.
Iaffaioli RV; Tortoriello A; Santangelo M; Turitto G; Libutti M; Benassai G; Frattolillo A; Ciccarelli PD; De Rosa P; Crovella F; Carbone I; Barbarisi A
Clin Oncol (R Coll Radiol); 2000; 12(4):251-5. PubMed ID: 11005695
[TBL] [Abstract][Full Text] [Related]
12. Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer: final analysis of a sicog phase III study.
Frasci G; D'Aiuto G; Comella P; Thomas R; Botti G; Di Bonito M; De Rosa V; Iodice G; Rubulotta MR; Comella G;
Br J Cancer; 2006 Oct; 95(8):1005-12. PubMed ID: 17047649
[TBL] [Abstract][Full Text] [Related]
13. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
Hitt R; Hornedo J; Colomer R; Mendiola C; Brandariz A; Sevilla E; Alvarez-Vicent J; Cortés-Funes H
Semin Oncol; 1995 Dec; 22(6 Suppl 15):50-4. PubMed ID: 8643971
[TBL] [Abstract][Full Text] [Related]
14. Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: a multicenter dose-escalation study. The Greek Breast Cancer Cooperative Group (GBCCG).
Kouroussis C; Xydakis E; Potamianou A; Giannakakis T; Kakolyris S; Agelaki S; Sara E; Malamos N; Alexopoulos A; Mavroudis D; Samonis G; Papadouris S; Georgoulias V; Panagos G
Ann Oncol; 1999 May; 10(5):547-52. PubMed ID: 10416004
[TBL] [Abstract][Full Text] [Related]
15. Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancer.
Jary M; Ghiringhelli F; Jacquin M; Fein F; Nguyen T; Cleau D; Nerich V; El Gani M; Mathieu P; Valmary-Degano S; Arnould L; Lassabe C; Lamfichekh N; Fratté S; Paget-Bailly S; Bonnetain F; Borg C; Kim S
Cancer Chemother Pharmacol; 2014 Jul; 74(1):141-50. PubMed ID: 24824852
[TBL] [Abstract][Full Text] [Related]
16. Results of a dose-intense phase 1 study of a combination chemotherapy regimen with cisplatin and epidoxorubicin including medroxyprogesterone acetate and recombinant interleukin-2 in patients with inoperable primary lung cancer.
Mantovani G; Macciò A; Lai P; Massa E; Massa D; Mulas C; Succu G; Mudu MC; Manca G; Versace R; Pisano A
J Immunother; 2000; 23(2):267-74. PubMed ID: 10746553
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
18. A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer.
Conte PF; Michelotti A; Baldini E; Salvadori B; Gennari A; Da Prato M; Tibaldi C; Salzano E; Gentile A
Semin Oncol; 1996 Oct; 23(5 Suppl 11):28-31. PubMed ID: 8893896
[TBL] [Abstract][Full Text] [Related]
19. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small-cell lung cancer: a phase I-II study. Southern Italy Cooperative Oncology Group.
Frasci G; Panza N; Comella P; Nicolella GP; Natale M; Manzione L; Bilancia D; Cioffi R; Maiorino L; De Cataldis G; Belli M; Micillo E; Mascia V; Massidda B; Lorusso V; De Lena M; Carpagnano F; Contu A; Pusceddu G; Comella G
J Clin Oncol; 1999 Aug; 17(8):2316-25. PubMed ID: 10561293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
